ストックスクリーナーアプリを入手
169.73
0.23%
0.39
アフターアワーズ：
168.00
-1.73
-1.02%
前日終値:
$169.34
開ける：
$170.64
24時間の取引高:
1.68M
Relative Volume:
0.77
時価総額：
$263.23B
収益：
$60.48B
当期純損益:
$10.40B
株価収益率:
50.97
EPS:
3.3297
ネットキャッシュフロー:
$8.05B
1週間 パフォーマンス:
+0.81%
1か月 パフォーマンス:
-3.80%
6か月 パフォーマンス:
+85.11%
1年 パフォーマンス:
+140.82%
1日の値動き範囲:
$168.47
$170.89
1週間の範囲:
$164.06
$170.89
52週間の値動き範囲:
$71.49
$212.71
Astrazeneca Plc Stock (AZN) Company Profile
Compare AZN vs LLY, JNJ, ABBV, MRK, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
169.73 | 262.63B | 60.48B | 10.40B | 8.05B | 3.3297 |
LLY
Lilly Eli Co
|
1,163.01 | 1.05T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
255.63 | 603.27B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
253.30 | 452.48B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
127.47 | 311.84B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
153.08 | 292.46B | 54.66B | 13.58B | 16.05B | 7.0171 |
Astrazeneca Plc Stock (AZN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-27 | 開始されました | Citigroup | Buy |
| 2025-10-27 | 再開されました | Jefferies | Buy |
| 2025-10-16 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2025-04-15 | 開始されました | Exane BNP Paribas | Outperform |
| 2025-02-13 | アップグレード | UBS | Neutral → Buy |
| 2025-02-12 | 開始されました | Morgan Stanley | Overweight |
| 2024-11-20 | アップグレード | UBS | Sell → Neutral |
| 2024-11-06 | アップグレード | Deutsche Bank | Sell → Hold |
| 2024-09-13 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2024-05-30 | 開始されました | Goldman | Buy |
| 2024-04-16 | アップグレード | Deutsche Bank | Sell → Hold |
| 2024-02-08 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2024-01-23 | 開始されました | Morgan Stanley | Overweight |
| 2024-01-16 | 再開されました | UBS | Sell |
| 2024-01-03 | ダウングレード | Jefferies | Buy → Hold |
| 2023-12-18 | 開始されました | HSBC Securities | Buy |
| 2023-09-25 | アップグレード | Jefferies | Hold → Buy |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-07-12 | アップグレード | UBS | Neutral → Buy |
| 2023-07-05 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2023-04-11 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | 開始されました | BMO Capital Markets | Outperform |
| 2022-09-15 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | アップグレード | Argus | Hold → Buy |
| 2022-06-14 | ダウングレード | UBS | Buy → Neutral |
| 2022-02-11 | アップグレード | DZ Bank | Sell → Hold |
| 2021-12-07 | ダウングレード | Jefferies | Buy → Hold |
| 2021-08-12 | 再開されました | JP Morgan | Overweight |
| 2021-04-12 | ダウングレード | Argus | Buy → Hold |
| 2021-03-16 | アップグレード | Jefferies | Hold → Buy |
| 2021-02-25 | アップグレード | UBS | Neutral → Buy |
| 2021-01-15 | 開始されました | Deutsche Bank | Buy |
| 2020-12-07 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | アップグレード | UBS | Sell → Neutral |
| 2020-11-11 | アップグレード | HSBC Securities | Reduce → Hold |
| 2020-09-29 | 開始されました | Berenberg | Buy |
| 2019-11-22 | 開始されました | SVB Leerink | Outperform |
| 2019-10-25 | アップグレード | Liberum | Hold → Buy |
| 2019-04-02 | ダウングレード | UBS | Neutral → Sell |
| 2019-02-05 | 開始されました | Exane BNP Paribas | Outperform |
| 2019-01-25 | アップグレード | Shore Capital | Hold → Buy |
| 2018-12-11 | 再開されました | Jefferies | Hold |
| 2018-10-09 | 開始されました | Guggenheim | Buy |
| 2018-08-16 | ダウングレード | Jefferies | Buy → Hold |
| 2018-03-19 | アップグレード | Jefferies | Hold → Buy |
| 2018-02-06 | 繰り返されました | Leerink Partners | Mkt Perform |
| 2018-02-05 | 繰り返されました | Bernstein | Outperform |
| 2018-01-18 | 繰り返されました | Leerink Partners | Mkt Perform |
| 2017-12-29 | アップグレード | JP Morgan | Neutral → Overweight |
| 2017-10-16 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | アップグレード | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | アップグレード | Bernstein | Mkt Perform → Outperform |
すべてを表示
Astrazeneca Plc (AZN) 最新ニュース
AstraZeneca stock steadies as oncology and vaccines underpin earnings momentum - Ad-hoc-news.de
Jefferies says September lung data can offset AstraZeneca trial failure - Proactive financial news
London Deal Activity Keeps Healthcare Stocks In Focus As AstraZeneca (LSE:AZN) Sets The Tone - Kalkine Media
Stay Ahead of the Game With Astrazeneca (AZN) Q2 Earnings: Wall Street's Insights on Key Metrics - Yahoo Finance UK
Royalty Pharma acquires royalty stake in AstraZeneca drug By Investing.com - Investing.com Canada
Royalty Pharma acquires royalty stake in AstraZeneca drug - Investing.com
Royalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from Neurimmune - The Manila Times
ASTRAZENECA : Jefferies gives a Buy rating - marketscreener.com
AstraZeneca stock trades steady as oncology and cardiovascular portfolio underpin growth - Ad-hoc-news.de
Earnings Preview: AstraZeneca to Report Financial Results on July 27 - 富途牛牛
AstraZeneca (AZN) Faces Changes Amid New U.S. Drug Tariff Regula - GuruFocus
AstraZeneca stock trades steady as oncology and vaccines underpin growth - Ad-hoc-news.de
PD-1 and PD-L1 Inhibitors Clinical Trial Pipeline Analysis Demonstrates 180+ Key Companies on the Horizon Expected to Transform the Oncology Space | DelveInsight - GlobeNewswire Inc.
AstraZeneca stock holds as earnings and pipeline milestones support valuation - Ad-hoc-news.de
AstraZeneca stock trades steady as oncology revenue supports 2025 outlook - Ad-hoc-news.de
ASTRAZENECA : JP Morgan gives a Buy rating - marketscreener.com
What Is Keeping AstraZeneca (LSE:AZN) At The Centre Of The Pharma Conversation? - Kalkine Media
AstraZeneca stock steadies as oncology growth supports guidance after latest quarterly update - Ad-hoc-news.de
Astrazeneca (AZN) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
AstraZeneca stock trades steadily as oncology and cardiovascular pipeline supports long term growth - Ad-hoc-news.de
Bronstein, Gewirtz & Grossman, LLC Is Investigating AstraZeneca PLC (AZN) And Encourages Investors to Connect - The National Law Review
AstraZeneca slips Monday, underperforms market - MarketWatch
AstraZeneca stock trades steadily as oncology and rare disease growth underpin earnings - Ad-hoc-news.de
What Is Putting AstraZeneca (LSE:AZN) At The Centre Of The Pharma Conversation? - Kalkine Media
AstraZeneca stock trades around recent highs as oncology growth supports valuation - Ad-hoc-news.de
AstraZeneca highlights rare diseases in $80bn revenue push - Financial Times
AstraZeneca PLC (AZN.L) Investor Outlook: Assessing a 25% Upside Potential Amid Robust Revenue Growth - DirectorsTalk Interviews
AstraZeneca stock steady as recent earnings and pipeline progress frame investor debate - ad-hoc-news.de
Bronstein, Gewirtz & Grossman, LLC Is Investigating AstraZeneca PLC (AZN) And Encourages Stockholders to Connect - Stockhouse
AstraZeneca’s Fresh Cancer Drug Boost: What’s Behind the Latest Share Momentum? - Kalkine Media
AstraZeneca stock holds as investors await fresh evidence - ad-hoc-news.de
AstraZeneca stock steady as oncology and rare disease pipeline supports growth - ad-hoc-news.de
Why Is AstraZeneca (LSE:AZN) Drawing Fresh Attention On Oncology Approvals? - Kalkine Media
AstraZeneca PLC (AZN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
AstraZeneca stock holds on to its earnings momentum - ad-hoc-news.de
AstraZeneca stock trades steady as oncology and rare disease pipeline underpins long term growth - ad-hoc-news.de
AstraZeneca stock trades steadily as oncology and rare disease pipeline underpins long term growth - ad-hoc-news.de
AstraZeneca PLC (AZN) Investigation: Bronstein, Gewirtz & Grossma - The National Law Review
AstraZeneca stock holds as 2025 revenue and profit stay in focus - Ad Hoc News
AstraZeneca stock edges higher as oncology and cardiovascular growth supports outlook - ad-hoc-news.de
Why Is AstraZeneca (LSE:AZN) Back in Healthcare Focus? - Kalkine Media
Why Is AstraZeneca (LSE:AZN) Leading the Blue-Chip Debate? - Kalkine Media
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against AstraZeneca PLC (AZN) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
AstraZeneca Tokenized Stock price today, AZNX to USD chart, marketcap and volume - CryptoSlate
Illumina, Inc., Formation Bio, Astrazeneca, Merck, and Eli Lilly and Company Expand Billion Cell Atlas Alliance with New Ai Drug Developers - marketscreener.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN - PR Newswire
Attractive Growth Profile Positions AstraZeneca PLC (AZN) as an Investment Bet - Yahoo Finance
What AstraZeneca (LSE:AZN) Says About The Mood Around Healthcare Stocks - Kalkine Media
Why Is AstraZeneca (LSE:AZN) Holding Firm Near Record Highs? - Kalkine Media
AZN Stock Quote Price and Forecast - CNN
Bronstein, Gewirtz & Grossman, LLC Encourages AstraZeneca PLC (AZN) Investors to Inquire about Securities Investigation - ACCESS Newswire
Astrazeneca Plc (AZN) 財務データ
収益
当期純利益
現金流量
EPS
0.51%
0.96%
大文字化:
|
ボリューム (24 時間):